ArticleBMC infectious diseases2025
Risk stratification for CMV reactivation in sepsis patients: development of an interpretable machine learning model.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytomegalovirus (CMV) reactivation in critically ill populations is associated with adverse outcomes. This study aimed to develop and validate an interpretable machine learning model to predict CMV reactivation within 28 days of ICU admission in sepsis patients, providing a risk stratification tool to optimize clinical management.
methodsA retrospective cohort study was conducted using data from intensive care unit (ICU) patients meeting SEPSIS-3 criteria. Key clinical variables, including acute physiology and chronic health evaluation Ⅱ(APACHE Ⅱscore), CMV IgG titer, CD4+ lymphocyte count, and corticosteroid use duration, were selected through univariate logistic regression. Seven machine learning models were developed, with the gradient boosting machine (GBM) demonstrating superior performance. Model interpretability was enhanced using Shapley Additive Explanations (SHAP) to identify critical predictors and visualize feature contributions.
resultsAmong 221 patients, 19.0% experienced CMV reactivation. The test set AUC values for GBM, logistic regression (LR), neural network (NN), support vector machine (SVM), random forest (RF), adaptive boosting (AdaBoost) and k-nearest neighbors (KNN) models were recorded as 0.761, 0.684, 0.673, 0.659, 0.65, 0.624, and 0.623, respectively. GBM model achieved the highest AUC in the test set, with robust calibration and net benefit of the GBM model in the test set exceeded that of the other models at threshold probabilities ranging from 10% to 60%. SHAP analysis identified the APACHE II score, corticosteroid use, CMV IgG levels, and CD4 + lymphocyte count as the top four important predictors. Kaplan-Meier curves demonstrated significant stratification between high- and low-risk groups (p < .05).
conclusionThis interpretable machine learning model provides accurate CMV reactivation prediction and clear insights into contributing factors. It has the potential to enhance early risk stratification and guide targeted management strategies for sepsis patients in ICU settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.